GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Vaccine production is nearly three years behind schedule at a federally owned plant in Montreal and the future of a deal ...
Canada’s panel of vaccine advisers has strongly recommended the new vaccines targeting the KP.2 strain, part of the Omicron lineage, for the previously vaccinated or unvaccinated at increased risk ...
Moderna said on Friday that Canada’s health regulator has approved its vaccine for respiratory syncytial virus (RSV) in adults 60 years and older, making it the country’s first authorized ...
Health officials say eligible residents can receive the COVID-19 vaccine at the same time as or at any time before or after ...
An initial 899,000 vaccine doses have been allocated for nine countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organizations say.
Two more cases of measles have been confirmed in New Brunswick, bringing the total number of cases to five. On Oct. 24, New ...
GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.